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Abbreviations 
AAR: area at risk  
ANAR: area not at risk  
BP: blood pressure 
[Ca2+]i: intracellular calcium 
cAMP: Cyclic adenosine monophosphate 
CNS: Central nervous system  
cTnI: cardiac Troponin-I 
CVD: cardiovascular disease 
DAPI: 4,6-diamido-2-phenylindole 
DORA: dual orexin (OX1R/OX2R) receptor antagonist 
ERG: ETS-related gene 
ERK: extracellular signal–regulated kinases  
FITC: fluorescein isothiocyanate-conjugated  
GPCR: G protein-coupled receptors 
HCRTR2: hypocretin receptor 2 
HEPES: (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
HR: heart rate  
ICV: intra-cerebroventricular  
LA: left atrium 
LCA: left coronary artery  
LSVP mmHg: left ventricular systolic pressure 
LV: left ventricle 
LVDP: left ventricular developed pressure  
LVEDP mmHg: left ventricular end diastolic pressure 
MAP: mean arterial pressure  
MAPK: mitogen-activated protein kinase  
MTC: multiple tissue cDNA  
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Myosin Light Chain: MLC 
NS: No supplement 
NYHA: New York Heart Association  
OR-A: Orexin A 
OR-B: Orexin B 
OX1R: orexin receptor 1 
OX2R: orexin receptor-2  
OXRs: orexin receptors 
PGK1: Phosphoglycerate Kinase 1  
PI3K: PI3 kinase 
PVN: paraventricular nucleus  
RA: right atrium  
RISK: reperfusion injury signalling kinase  
RPP: rate pressure product 
RPP: rate pressure product 
RSNA: renal sympathetic nerve activity 
RT-PCR: reverse transcription-polymerase chain reaction 
RV: right ventricle  
SNS: sympathetic nervous system 
Troponin: Tn 
TTC: Triphenyl-tetrazolium chloride  
Perspectives Section 
(i) Several cardiovascular drugs exert their cardiac actions via GPCRs, and orexins acting
via their GPCR receptors can affect the heart centrally. In this study we tested whether
orexins and their receptors can exert a direct effect at cardiac level.
(ii) The human and rat heart constitutes a source of orexins and expresses functional OXRs.
OR-B can exert direct cardioprotective effects in both ex vivo and in vivo rat heart models. In
adults with heart failure there was a significant negative correlation between the severity of
clinical symptoms (NYHA class) and OX2R expression in the human heart.
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(iii) Based on the findings from our study, the use of orexin antagonists warrants further
assessment and careful monitoring for CVD adverse effects, particularly in heart failure
patients.
Abstract 
Orexins/hypocretins exert cardiovascular effects which are centrally mediated. In this study 
we tested whether orexins and their receptors may also act in an autocrine/paracrine 
manner in the heart exerting direct effects. Quantitative RT-PCR, immunohistochemical and 
Western blot analyses revealed that the rat heart expresses orexins and orexin receptors. In 
isolated rat cardiomyocytes, only orexin-B (OR-B) caused an increase in contractile 
shortening, independent of diastolic or systolic calcium levels. A specific orexin receptor-2 
(OX2R) agonist ([Ala11, D-Leu15]-Orexin B) exerted similar effects as OR-B, whereas a 
specific OX1R antagonist (SB-408124) did not alter the responsiveness of OR-B. Treatment 
of the same model with OR-B resulted in a dose-dependent increase of myosin light chain 
and troponin-I phosphorylation. Following ischaemia/reperfusion in the isolated Langendorff 
perfused rat heart model, OR-B, but not OR-A, exerts a cardioprotective effect; mirrored in 
an in vivo model as well. Unlike OR-A, OR-B was also able to induce ERK1/2 and Akt 
phosphorylation in rat myocardial tissue and ERK1/2 phosphorylation in human heart 
samples. These findings were further corroborated in an in vivo rat model. In human subjects 
with heart failure, there is a significant negative correlation between the expression of OX2R 
and the severity of the disease clinical symptoms, as assessed by the New York Heart 
Association (NYHA) functional classification. Collectively, we provide evidence of a distinct 
orexin system in the heart that exerts a cardioprotective role via an OR-B/OX2R pathway.  
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INTRODUCTION 
Cardiovascular disease (CVD), including myocardial infarction, is the leading cause of 
morbidity and mortality in the Western world (1,2). Orexins, also referred to as hypocretins, 
exist in two functional forms, i.e. orexin A (OR-A) and orexin B (OR-B), which are derived 
from a common 130 amino acid precursor peptide (3,4)  and exert their actions by activating 
the orexin-1 (OX1R) and orexin-2 (OX2R) receptors. OXRs belong to the GPCR superfamily 
(3) and are distributed throughout both central and peripheral sites where they regulate 
endocrine, metabolic and cardiovascular functions (5–7). Of note, several established 
cardiovascular drugs exert their cardiac actions via GPCRs, such as the muscarinic, 
angiotensin, adrenergic and endothelin receptors (8). 
Growing evidence indicates that central orexin neurons are implicated in cardiovascular 
regulation (5).For example, in the central nervous system (CNS), both orexin and OX2R-
containing nerve fibres have been identified in the paraventricular nucleus (PVN) (9), an 
area which constitutes a vital central site for integration of sympathetic outflow and 
cardiovascular function(10–12)(13–15) (16) (17). Thus, although orexins can influence the 
autonomic control of the cardiovascular system, little is known about any direct effects of 
orexins in the heart.  
 
 
We and others have provided evidence for a wide distribution of orexins and their receptors 
peripherally (18–20). We have also demonstrated the presence of OXRs in human adipose 
tissue, where they modulate adipogenesis and adipose tissue metabolism (7). Herein, we 
hypothesised that orexins may also exert direct cardiac effects and we sought to investigate 
the expression and function of cardiac OXRs using in vitro, ex vivo and in vivo models, 
corroborating this with clinical data. 
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Materials and Methods 
Drugs and experimental solutions 
Study treatment agents were: OR-A, OR-B (Phoenix Peptides), OX2R agonist ([Ala11, D-
Leu15]-Orexin B; Tocris), OX1R antagonist (SB-408124; Tocris), wortmannin (PI3Kinase 
inhibitor; Sigma-Aldrich) and MAPK inhibitor U0126 (Tocris). According to the manufacturer’s 
specifications on biological activity, the used OX2R agonist ([Ala11, D-Leu15]-Orexin B; 
Tocris) is a “highly potent and selective OX2 receptor agonist; displays 400-fold selectivity 
over OX1 receptors. EC50 values are 0.13 and 52 nM for human OX2 and OX1 receptors 
respectively”. Similarly, the used OX1R antagonist (SB-408124) is a “selective non-peptide 
orexin OX1 receptor antagonist (Kb values are 21.7 and 1405 nM for human OX1 and OX2 
receptors respectively)”. Triphenyl-tetrazolium chloride (TTC, Sigma-Aldrich) was used to 
determine the infarct size following ischemia and reperfusion. All other reagents used were 
of the highest purity commercially available. 
 
Animal Experiments 
All animal experiments were performed in accordance with UK legal requirements and the 
guidelines from Directive 2010/63/EU of the European Parliament on the protection of 
animals used for scientific purposes. This investigation also conforms to the guidelines for 
the welfare of animals in experimental neoplasia as they have been developed by the United 
Kingdom Coordinating Committee of Cancer Research (UKCCCR). Adult male Wistar rats 
(250-300 g) were housed in environmentally controlled conditions (22±2°C, humidity 40–
60%) under a 12:12-h light-dark schedule (lights on 0600). After a week of habituation to 
these conditions, rats were sacrificed using cervical dislocation. Hearts were immediately 
removed for the following studies: (a) dissection and immediate snap-freezing for later tissue 
analysis; (b) isolation of ventricular cardiomyocytes by enzymatic digestion; (c) immersion in 
ice-cold oxygenated Tyrode’s solution and then perfusion via the aortic cannula in the 
modified Langendorff model with Tyrode’s solution at 37oC, as previously described (21). In 
brief, contractile parameters were measured by insertion of a fluid-filled latex balloon through 
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the left atrium into the left ventricle, this was connected to a pressure transducer (MTL0380, 
ADInstruments Ltd, UK) and the balloon volume was adjusted to give end-diastolic pressure 
of <10 mmHg. Aortic perfusion pressure was monitored with a second pressure transducer 
in series with the aortic cannula. Data were continuously recorded using a Power Lab 8 
preamplifier/digitiser (ADInstruments Ltd, UK). Hypothalamic dissection took place as 
previously described (22). All procedures were approved by the ethics committee and 
complied with the University’s care and welfare guidelines, in strict accordance with the 
Home Office Guidance (PPL 70/7175) on Research and Testing using animals and the 
Animal (Scientific Procedures) Act, 1986 and the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996). 
 
Human Cardiovascular Multiple Tissue cDNA (MTC) Panel 
Commercially available human cardiovascular multiple tissue cDNA (MTC) panel (Clontech) 
were used for this study. All tissues were normal (i.e. non-diseased) and the amount of 
pooled patients varied from 11 up to 32. The sets of primers used for RT-PCR amplification 
were (i) OX1R sense 5’-ccttcctggctgaagtgaag-3’ and antisense 5’-agtgggagaaggtgaagcag-3’; 
(ii) OX2R sense 5’-gtcgcaactggtcatctgct-3’ and antisense 5’-cgtcctcatgtggtggttct-3’. 
 
Harvesting of single-cell mRNA and cDNA synthesis 
Under the microscope, single rat cardiomyocytes (n=6) were harvested via the patch clamp 
micro-electrode pipette, without losing the gigaseal to prevent contamination with 
extracellular fluid (23). Subsequently, the pipette contents were expelled into a sterile 0.5 ml 
tube.  
 
 
Polymerase Chain Reaction (PCR) 
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Total RNA from different rat heart chambers (n=3) was extracted and cDNA synthesis was 
performed. PCR reactions were carried out as previously described (7). 
 
Immunofluorescence for orexins and orexin receptors in cardiomyocytes 
Adult rat cardiomyocytes, seeded on glass cover-slips were fixed with 4% paraformaldehyde 
in PBS. The primary rabbit antiserum OR-A and OR-B (Phoenix Europe GmbH, Karlsruhe, 
Germany) and the primary goat polyclonal OX1R (Santa Cruz Biotechnology Inc., USA) and 
a monoclonal OX2R antibody (Abcam, UK) were used at a 1:500 dilution. All dilutions were 
made in 3% BSA in PBS-0.01% Triton X-100. Specimens were incubated with primary 
antibody for 60 min, then washed three times with PBS (5 min each time) before incubation 
with anti-rabbit IgG-fluorescein isothiocyanate-conjugated (FITC) and Texas Red anti-goat 
secondary antibody (Vector laboratories, Peterborough, UK) for 45 min. The slides were 
then thoroughly rinsed with PBS, and the cell nuclei were visualized by applying the DNA-
specific dye 4,6-diamido-2-phenylindole (DAPI) at a final concentration of 1.5 µg/ml. 
 
Immunohistochemistry for orexin and orexin receptors in the rat heart 
Whole heart tissue sections from adult rats (n=3) were cut at 3 μm. Endogenous peroxidase 
was blocked by incubating sections in a 1.5% H2O2 solution for 20 min. The detection 
system used was an immunoperoxidase-based system (Vector Universal Elite ABC kit) with 
a diaminobenzidine tetrahydrachloride visualisation agent. Sections were incubated in 
primary antibody (OX1R, OX2R, OR-A and OR-B) for 60 min at room temperature. Sections 
were then washed for 2x5 min in buffer. Secondary biotinylated antibody was applied for 30 
min at room temperature. The avidin-biotin complex solution was then applied to the 
sections and incubated for 30 min at room temperature (Vector Elite ABC reagent). DAB 
solution was prepared according to the manufacturer’s instructions and applied to the 
sections for 5 min. Sections were then dehydrated, cleared and mounted.  
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For controls, rat spleen, testes (positive controls) and thymus (negative control) were stained 
using paraffin-embedded tissues from US Biomax (#RA162, MD, USA). Furthermore, we 
have repeated the OR-A staining on rat heart array (#TR031; US Biomax MD, USA). 
 
Western Blotting for PPO and Orexins 
Protein lysates from rat brain, rat heart and human myometrium were separated using 
SDS/polyacrylamide gel electrophoresis (SDS/PAGE) (15% polyacrylamide) under reducing 
conditions and then transferred onto immunoblot nitrocellulose membrane. Blocking of non-
specific binding was achieved by placing the membrane in a blocking buffer (1% BSA in 1X 
TBST) at 4oC overnight. The following day, membrane was rinsed with TBST for 5-10 min. 
Membranes were then incubated with primary anti-rabbit OR-A and OR-B antibodies 
(Phoenix Peptides) diluted 1:500 and further incubated at 4oC overnight under gentle 
agitation. The next day, after rinsing the membrane three times in TBST for 10 min to 
remove unbound primary antibodies, the membranes were exposed to anti-rabbit IgG- HRP 
conjugate (Sigma Aldrich) (diluted 1:2000 in blocking solution) for 1 h at room temperature. 
Detection of immunocomplexes took place using the ECL method, exposing x-ray film (Fuji) 
at different time points (30 sec to 1 min) following by developing. Molecular weight 
approximations are taken by comparing the stained bands to that of the marker proteins. 
 
Orexin mediated signalling in cardiomyocytes 
Following the isolation of calcium tolerant cardiomyocytes (n=6), the cells were treated in a 
concentration (0.01-100 nM) and time (0-60 min) dependent manner with both OR-A and 
OR-B. Following these optimisation experiments, orexin-induced phosphorylation of various 
signalling cascades i.e. Akt, ERK1/2, Troponin-I and Myosin Light Chain were determined by 
western blot analyses, as described previously (24). 
 
Measurement of cell contraction and intracellular calcium 
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Contraction and intracellular calcium were determined in isolated ventricular cardiomyocytes 
(n=6), as previously described  (21). Cells were classified as either contractile or non-
contractile in response to electrical stimulation. To measure [Ca2+]i, myocytes were loaded 
with fura-2 and excited alternately at 340 and 380 nm with a monochromator and emitted 
light collected at > 520 nm and measured using a photomultiplier tube (Photon Technology 
International). Contraction strength is shown as percentage cell shortening and [Ca2+]i as 
Fura2 ratio. 
 
Determination of infarction following ischaemia/reperfusion in the isolated 
Langendorff perfused rat heart 
All experiments lasted 195 min. Hearts were allowed to stabilize for 30 min with the standard 
Tyrode’s solution perfusion. Contractile parameters from the data files were calculated by 
averaging a minimum of 6 cycles per data point to obtain the mean value for left ventricular 
systolic pressure, LVSP mmHg, and left ventricular end diastolic pressure, LVEDP mmHg 
(measured at t0, t30, t40, t75, t85, t100, t130, t160, and t195 min). The difference between 
these two pressure values represented the left ventricular developed pressure (LVDP, 
mmHg). Heart rate (HR, beats.min-1) was determined at the same time-points together with 
the rate pressure product (RPP, mmHg), which was calculated by multiplying the LVDP and 
HR (average value of LV Developed Pressure is obtained from averaging both systolic and 
diastolic values, then the mean is multiplied by HR to obtain RPP).  
Global ischaemia was produced for 30 min by stopping flow of physiological solution to the 
heart. At the end of reperfusion, the heart was frozen at -20oC before being sliced into 2mm 
thick transverse sections and stained with 2% TTC, which reacts with intracellular 
dehydrogenases present in viable cells producing a red pigment and staining viable tissue 
red (whereas infarcted tissue remains pale) and then fixed in 10% formalin overnight to 
enhance the contrast. Each section was then photographed with a digital camera and then 
traced onto a clear acetate sheet to determine infarct size (% infarct area= infarct area on 
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each slice/total area of the heart slice X 100) (25); the area was calculated using computer-
assisted planimetry [NIH image 1.57] (26–28). 
For the inhibitor studies the rats were randomly assigned to one of the following groups:  1) 
control group, where they were subjected to 30 mins of global ischaemia followed by 120 
mins of reperfusion, and the treated heart groups, which received inhibitor (wortmannin;  
1umol/l or  U0126; 10umol/l) together with OR-B perfusion which was added to Tyrode’s 
buffer after stabilisation and perfused for 10 mins prior to 30 min global ischaemia and 
switched back to normal Tyrode’s during 120 mins reperfusion. In addition, some hearts only 
received the inhibitors (wortmannin or U0126) to rule out any influence they may have 
directly upon infarct size. 
 
Inducing ischemia in rats in vivo 
Rats were anesthetized with 3% isoflurane inhalation and then intubated via a tracheostomy 
and ventilated with a mixture of O2 and 1.5-3% isoflurane, using a rodent ventilator. A left 
thoracotomy was performed through the 4th intercostal space, pericardium opened and the 
left coronary artery (LCA) located and ligated with a 4-0 silk suture. The ligation was 
confirmed successfully when the anterior wall of the left ventricle (LV) turns pale around the 
area that was tied off using a snare. Following 30 minutes of regional ischaemia the snare 
was released and blood allowed to flow freely during 120 minutes of reperfusion. At the end 
of the experimental protocol the hearts removed and perfused onto the Langendorff system 
for staining. The ligation was tied off and hearts perfused with 1% Evans blue to demarcate 
the area at risk, followed TTC staining to identify the viable tissue staining deep red. The 
infarct area within the risk area was then calculated (I/R %). The same surgical procedure 
was followed for sham group without occlusion of the LCA (data not shown).   
 
Determination of infarction following ischaemia/reperfusion in the in vivo rat heart 
At the end of reperfusion, the rat was overdosed with pentobarbital and the heart was rapidly 
removed and mounted onto the Langendorff apparatus as above. The left anterior 
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descending artery was ligated, 1 ml of 0.25% Evans Blue (in phosphate-buffered saline) was 
then injected into the heart and allowed to perfuse followed by normal Tyrode’s for a further 
2 minutes to delineate the area not at risk staining it blue (29). The heart was stored at -20oC 
before being sectioned into 2mm sections and stained with TTC to determine the infarct size 
as stated above. The percentage infarct tissue (I) within the area at risk (AAR) was 
calculated as I/AAR %. Furthermore, the ischaemic area (AAR) was distinguished from the 
area not at risk (ANAR).  
 
Orexin in the human heart  
The clinical study was approved by the Research Ethics Committee South-Central Oxford C 
(11/SC/0140). All participants provided written informed consent, in accordance with the 
Declaration of Helsinki. 
 
Orexin gene expression in human myocardial tissue  
To explore whether our findings from the cell cultures and animal model could be of 
relevance to cardiovascular disease in humans, we investigated OX2R gene expression 
levels in human myocardium samples. A cohort of 54 patients undergoing coronary artery 
bypass grafting with available myocardial cDNA library was used for this purpose (Table 1); 
relative expression was calculated using the Pfaffl method, with PGK1 as housekeeping 
gene (30). 
 
Orexin signalling in the human myocardium 
To examine the direct effects of OR-A and OR-B on intracellular signalling in the human 
heart, human myocardial tissue samples were collected from the right atrial appendage of 8 
patients undergoing cardiac surgery. These myocardial tissue samples were washed in ice-
cold Krebs HEPES buffer and then cut into thin strips containing all myocardial layers. The 
tissue was first equilibrated for 10 min in Krebs HEPES buffer at 37oC and then incubated for 
20 min in the presence or absence of human recombinant OR-A (100 nM) or OR-B (100 nM) 
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(Phoenix Pharmaceuticals Inc., Burlingame, CA, USA). At the end of the experiment, 
incubated tissue samples were collected and stored at -80oC until assayed. Western 
immunoblotting was used to examine the direct effects of OR-A and OR-B on phospho-Akt 
(Ser473), total-Akt, (Cell Signaling, Danvers, MA), and phospho/total ERK1/2 (Abcam, 
Cambridge, England, United Kingdom) in human myocardial tissue. Briefly, myocardial 
tissue samples were homogenized for 30 seconds using a pre-cooled electric Polytron 
homogenizer in 220 μl of lysis buffer (Invitrogen, UK) containing a protease plus 
phosphatase inhibitor cocktail (Roche Applied Science). Homogenates were spun at 13,000 
rpm for 10 min at 4 ºC. The protein concentration of the supernatants was then measured 
using the BCATM Protein Assay kit (Pierce, UK). Protein lysates were separated on 12% 
gradient SDS-NuPAGE gel (Invitrogen, UK), and proteins transferred to polyvinylidene 
difluoride membranes (Amersham, UK Ltd.), followed by blocking with 5% powdered 
skimmed milk. The membranes were incubated with the respective primary antibodies 
overnight and immunodetection of the primary antibodies was performed with horseradish-
peroxidase-conjugated secondary antibodies (Promega), and enhanced chemifluorescence 
(Amersham Bioscience UK Ltd.), and quantified in relation to the house-keeping protein 
GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA). 
 
Statistical Analysis  
All results are expressed as mean ± standard error (SEM), unless indicated otherwise. For 
western blotting experiments, the densities of the immunoreactive bands were measured 
using a scanning densitometer coupled to scanning software (ImageQuant; Molecular 
Dynamics, Amersham Pharmacia, UK). Data were evaluated as in the study by Maulik et al 
(31). Statistical analyses amongst the Langendorff model perfused groups were performed 
using one-way ANOVA followed by Bonferroni’s post hoc test with significance determined at 
the level of P<0.05.  
 
RESULTS 
14 
 
Detection of cardiac prepro-orexin and orexin receptors  
Using qRT-PCR we demonstrate that both orexin receptors are expressed in the rat heart. 
Using rat hypothalamus as positive control, the expression of OX1R was significantly less in 
the heart (P<0.001), whereas OX2R expression levels were similar between the heart and 
the hypothalamus (Figure 1A). Both OXRs were uniformly expressed throughout the rat 
heart including the left ventricle (LV), left auricle (also known as left atrial appendage), 
interventricular septum, right ventricle (RV), and right auricle (Figure 1D). Single cell PCR 
from cardiomyocytes revealed expression of both OXRs in single cells investigated (Figure 
1E).  
Using Western blotting, we also confirmed the expression of OXRs at the protein level in 
total rat heart and cardiomyocyte cell lysates (data not shown). Immunohistochemical 
analysis of ventricular sections using specific antibodies for OX1R (Figure 1B-I) and OX2R 
(Figure 1B-II) revealed a widespread cytoplasmic and membrane distribution of both OXRs 
across the rat ventricle. Cellular distribution of OXRs was further investigated in rat 
cardiomyocytes in vitro. Immunofluorescence revealed a similar distribution of OX1R (Figure 
1C-I) and OX2R (Figure 1C-II). This is consistent with the expression of GPCRs in the 
cytoplasm (due to trafficking or internalisation), as well as on the cell membrane (32). We 
then proceeded to study the expression of OXRs in the human heart using a cardiovascular 
multiple tissue cDNA panel demonstrating expression of both OXRs in multiple human 
cardiac compartments (Figure 1F).  
We also demonstrate that prepro-orexin is expressed as a 302bp PCR product in the left 
ventricle (LV), left atrium (LA), interventricular septum, right ventricle (RV), and right atrium 
(RA) of the rat heart (Figure 1G). We have used Western blotting to demonstrate that the 
prepropeptide can be cleaved into full length OR-A (Figure 1H) and OR-B (Figure 1I), with 
molecular weights of approximately 3.5 kDa and 2.9 kDa, respectively. We then assessed 
the protein expression using immunohistochemistry. Antibodies were validated using rat 
thymus as negative control and rat spleen and rat testes as positive control (Figure 1J; 
Supplementary Figure 2). Subsequent immunohistochemical analysis of rat ventricular 
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sections revealed protein expression of both cleaved peptides across the ventricle (Figure 
1K; Supplementary Figure 2). Similar expression was evident in individual cardiomyocytes 
(Figure 1L).  
 
Cardiomyocyte contractility and calcium measurements 
Superfusion of cardiomyocytes with Tyrode’s solution containing 10 nM OR-B increased the 
shortening of twitch contraction (Figure 2A), from 15.2±1.2% to 20.6±1.7% (n=6, P<0.01; 
Figure 2B). This was not associated with any change on either the amplitude (Figure 2A) or 
the rate of the Ca2+ transient decline (n=6, P=NS; Figure 2C). OR-A had no effect on the rat 
cardiomyocyte cell length even with concentrations as high as 100 µM (data not shown; 
P=0.07). The OR-B effect was replicated using the specific OX2R agonist ([Ala11, D-Leu15]-
Orexin B) (Figure 2D), whilst it was not blocked by an OX1R specific antagonist (SB-408124) 
(Figure 2E), suggesting that these effects are predominantly mediated via an OR-B/OX2R 
pathway. 
Furthermore, OR-B, but not OR-A (data not shown), significantly induced phosphorylation of 
troponin I at Ser23/Ser24 in cardiomyocytes. This effect was dose-dependent, with a 
maximum activation at 100 nM of OR-B (P<0.001; Figure 2F). Similarly, OR-B, but not OR-A 
(data not shown), induced significant phosphorylation of the myosin light chain (MLC) at 
Ser19 with maximal effects at 100 nM and 15 min (P<0.001; Figure 2G).  
 
OR-B exerts a cardioprotective effect  
 
In both the isolated rat heart and the in vivo rat model, we measured left ventricular 
developed pressure (LVDP), LV pressure decay and HR. The rate pressure product (RPP) 
was then calculated; this was used as a clear and direct indication of the energy demand of 
the heart and, thus, a good measure of the energy consumption of the heart pre- and post-
ischaemia. 
Initially, pre-treatment with either OR-A, OR-B or OX2R agonist, prior to the ischaemic insult, 
did not alter the haemodynamic parameters or HR between any of the groups (data not 
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shown). Contractile parameters were recorded at various time points throughout the 
experimental protocol (Supplementary Figure 1). Following 30 min of global ischaemia in the 
isolated Langendorff perfused rat heart model, the expected decline in cardiac function 
during reperfusion, as observed in the control hearts, was not affected by pre-treatment with 
OR-A (Figure 3A). In contrast, the pre- and post- treatment group for both OR-B and the 
OX2R agonist resulted in significantly improved recovery compared to control during 
reperfusion (P<0.05; Figure 3A-B). This was further replicated in the in vivo rat model where 
the control group (saline treated) demonstrated poor cardiac functional recovery and cardiac 
function following 30 min of regional ischemia and 120 min reperfusion, whereas the OR-B 
pre-treated group [bolus injection (i.v.) of OR-B (100 nM) 10 min prior to regional ischaemia] 
showed significant improvement in functional recovery during reperfusion (P<0.05; Figure 
3C). Concentration dependent effects were noted with OR-B (20–100nM), with a maximal 
response at 100 nM (data not shown). 
 
Effects of OR-B reducing the LV infarct size  
 
In isolated rat heart model pre-treated with OR-B for 10 min prior to global ischaemia and 
reperfusion the LV infarct size was reduced from 61.5±3.0% in the control to 22.6±1.9% in 
the treated group (P<0.001; Figure 3D). In addition, the OR-B post-ischaemic treatment was 
just as effective at providing myocardial protection as pre-treatment, since it also significantly 
reduced the LV infarct size to 21.8±3.9% (P<0.001; Figure 3E). The OX2R specific agonist 
exhibited a similar protective effect to OR-B treatment, inducing a reduction in LV infarct size 
both during pre-treatment (25.7±3.6%) and at the start of reperfusion (34.7±3.1%, both P 
values <0.001 compared to control; Figure 3D-E). However, pre-treatment with OR-A alone 
showed no significant reduction compared to control (58.3±3.0% versus 61.5±3.0%, 
respectively; P=NS) in the LV infarct size (Figure 3D). Moreover, in the in vivo model pre-
treatment with a bolus injection (i.v.) of OR-B (and of ORX2Ra, but not of OR-A) 10 min prior 
to regional ischaemia and reperfusion significantly reduced the %LV infarct size compared to 
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the control (saline) group (66.7±3.0% versus 26.8±14.9% in the control and OR-B treated 
group, respectively; P<0.001; Figure 3F).  
 
Involvement of distinct signalling pathways in myocardial protection 
The isolated rat heart model was pre-treated either with an OX1R specific antagonist or a 
PI3 kinase (PI3K) inhibitor (wortmannin) in the presence or absence of OR-B prior to 
ischaemia reperfusion. Pre-treatment with either the OX1R specific antagonist or 
wortmannin alone showed no change in functional recovery compared to the control group 
(Figure 4A) and no effect on the %LV infarct size (61.5±3.0% in the control group versus 
61.8±1.9% with OX1R antagonist alone, and 56.5±1.5% with wortmannin alone; P=NS, 
Figure 4B). Pre-treatment with OR-B together with wortmannin showed no myocardial 
protection on cardiac functional recovery (P=NS; Figure 4A); and, abolished the OR-B 
protective effect on LV infarct size (P=NS, Figure 4B), suggesting the importance of the 
PI3K/Akt pathway in OR-B induced cardioprotection. Improved functional recovery with OR-
B pre-treatment was not inhibited by the simultaneous administration of an OX1R specific 
antagonist (P<0.05; Figure 4A). Similarly, the OR-B protective effect on %LV infarct size was 
not blocked by the OX1R specific antagonist (P<0.001; Figure 4B). Both these findings 
suggest that the noted effect is OX2R specific.  
Given that ischaemic preconditioning protects the heart by phosphorylating the pro-survival 
kinases Akt and ERK1/2 at reperfusion, we investigated further whether orexins can affect 
their phosphorylation (33). Treatment with OR-B increased the phosphorylation of both Akt 
and ERK1/2 compared to basal levels (P values <0.001; Figure 4C-E); in contrast to OR-A 
which had no significant effect on ERK1/2 (Figure 4E) and Akt (data not shown). The OR-B 
effect was concentration-dependent (Figure 4D). The time course for the ERK1/2 activation 
was for 3, 5, 10, and 15 minutes. The involvement of a MAPK pathway was further 
corroborated using the selective MAPK inhibitor U0126, demonstrating that inhibition of the 
MAPK pathway using U0126 abrogates the protective effect of OR-B on LV infarct size 
(Figure 4F). 
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OX2R expression in patients with heart failure, and involvement of the ERK1/2 
pathway 
To further evaluate the potential implication of orexins and their receptors in cardiac disease 
in humans, we studied OXR downstream signalling and expression in cardiac tissue 
samples from adult patients undergoing cardiac surgery and coronary artery bypass grafting. 
In the context of these studies, all human myocardial tissue samples were collected from the 
right atrial appendage during cardiac surgery.  
Using Western blotting, we examined the direct effects of OR-A and OR-B on the 
phosphorylation of Akt and ERK1/2 in heart tissue samples from 8 patients. Treatment with 
OR-A or OR-B did not change Akt phosphorylation compared to basal levels (Figure 5A), 
whilst only OR-B significantly increased ERK1/2 phosphorylation compared to control (non-
treated heart tissue; P <0.05; Figure 5B).   
In addition, we measured OXR expression levels in heart tissue samples from heart failure 
patients undergoing coronary artery bypass grafting (n=54; Table 1). Our results 
demonstrated a negative correlation between the severity of heart failure symptoms and the 
expression of OX2R. As such, when patients were categorised using the New York Heart 
Association (NYHA) functional classification of heart failure (classes I to IV based on 
increasing severity of clinical symptoms) there was a significant decrease of OX2R in NYHA-
II compared to NYHA-I and in NYHA-III/IV compared to NYHA-II and NYHA-I (P values 
<0.05; Figure 5C). 
 
Discussion 
In this study, we have shown that the heart constitutes a source of orexins and expresses 
functional OXRs. Moreover, our experiments revealed that OR-B can exert direct 
cardioprotective effects in both ex vivo and in vivo rat heart models.  
Indeed, using the Langendorff perfused rat heart model, pre- and post- myocardial 
ischaemia treatments with both OR-B and a selective OX2R agonist resulted in significantly 
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increased RPP which is a direct indication of the energy demand of the heart and, thus, a 
good measure of the energy consumption of the heart pre- and post-ischaemia. 
In the case of the ex vivo studies that replicate the in vivo results, additional interactions 
between sympathetic activity, which is increased in ischaemia (34), and OXR signalling 
through cAMP (35) cannot be ruled out. Additionally, treatment of ventricular cardiomyocytes 
with OR-B, but not OR-A, lead to significantly increased Tn-I and MLC phosphorylation, 
followed by a concomitant increase in the strength of their twitch contraction. Of note, these 
findings agree with previous studies demonstrating that changes in the phosphorylation of 
key cardiac regulatory proteins can affect cardiac function (36,37).   
This is the first observation of a differential specificity of OR-A and OR-B in the heart. OR-A 
activates both OX1R and OX2R receptors with similar potencies (~36 nM), whereas OR-B 
selectively activates OX2R compared to OX1R (~420 nM) (38). Both receptors belong to the 
GPCR superfamily and are highly promiscuous in terms of their G protein coupling 
characteristics (39). These tend to be cell- and tissue-specific and influence subsequent 
activation of downstream signalling pathways. For example, we have previously shown that 
expression of human OX2R is regulated by a complex involving a proximal PKA/PKC-
regulated promoter and a distal promoter regulating tissue-specific expression of alternative 
transcripts which in turn post-transcriptionally regulate receptor levels (40). Therefore, future 
studies are required to provide further insight into the regulation of the promoter of OX2R in 
the myocardium. 
Moreover, a dichotomous role of OXRs is evident in the rat brain, where OX1Rs mediate the 
neurobiological effects that drive drug seeking, whereas OX2Rs play a crucial role in 
sleep/wake cycle regulation and arousal (41). Interestingly, OR-A, but not OR-B, can 
activate electrophysiologically the subfornical organ of rat neurons (42). In a more recent 
study, OR-A (100 nM) and OR-B (100 nM) increased leptin gene expression in differentiated 
preadipocytes by 49.9% and 71.3%, respectively (43), indicative of differential modulation of 
transcriptional responses by these two peptides. 
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This phenomenon has been previously described for other GPCRs. In the case of smooth 
muscle cell CRH-receptors, urocortin, but not CRH, activated the MAPK signal transduction 
pathway despite similar binding affinities (44). Thus, it is possible that differences on OR-A 
and OR-B responses could also be influenced by the cardiac microenvironment, leading to 
alternative coupling of G proteins and activation of distinct signalling pathways. In previous 
studies, we have shown that OX2Rs can differentially couple to Gq, Gi/o and Gs proteins in 
different tissues (19,22,39). Emerging studies have also shown that OXRs can form 
functional dimers. It is possible that dimerization can also take place at the cardiac level and 
therefore influence pharmacological properties, such as the affinity of the receptors for 
orexin ligands, as well as cellular distribution and trafficking (45). Finally, polymorphisms of 
the OX2R gene have also been described previously (46). To this date, dimerization or 
polymorphisms have not been explored in the myocardium. Future studies should determine 
whether dimerization or polymorphisms of cardiac OXRs may affect ligand binding, or 
indirectly affect ligand binding by altering receptor structure.   
In the present study, using an OX1R antagonist and an OX2R agonist, we conclude that the 
primary signalling at the rat heart is mediated via an OR-B/OX2R pathway. OXRs are able to 
activate certain key plasticity-regulating cascades, such as PI3K and ERK, and p38 MAPK. 
Here, pre-treatment with wortmannin abolished the OR-B protective effect on LV infarct size; 
suggesting the involvement of the PI3K/Akt pathway in OR-B induced cardioprotection. This 
signalling pathway has been implicated in myocardial protection; and is referred to as the 
reperfusion injury signalling kinase (RISK) pathway (33). Mediators that target the activation 
of the RISK (PI3K/Akt) pathway have been also shown to ameliorate recovery following 
ischaemic stress (25,47). In our study, OR-B, but not OR-A, was able to induce the 
phosphorylation status of both Akt and ERK1/2. Our data contradict previous studies 
showing that both orexin peptides can increase Akt phosphorylation. For example, in a study 
of neuronal cell cultures OR-B was more potent than OR-A, but the maximal effect of both 
peptides on the Akt activation was very similar (48). This apparent contradiction could be 
attributed to the fundamental differences between cardiomyocytes and neuronal cells 
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including morphological polarity, shape and function of action potentials, synaptic and 
homeostatic plasticity; not to mention the spatial expression of orexin receptors in the brain 
(49). As such, it is plausible that orexins exert their effect in an organ- and cell-specific 
manner. 
The OR-B selectivity in post-translational modification of key mediators is corroborated by 
previous studies in other tissues. Indeed, in the human testis, when IP3 turnover was 
measured, OR-B exerted a more potent effect compared to OR-A (18). Similarly, in human 
H295R adrenocortical cells diverse roles have been noted for OR-A and OR-B in terms of 
activation of MAPKs and cortisol release; i.e. only OR-A (at 1nM) activated ERK1/2 and p38 
(50).   
Based on our findings, herein we propose the presence of a signalling pathway involving 
OX2R-ERK1/2-MLC in the heart with a net effect of increased Ca2+ sensitivity and cell 
length/contractility following OR-B superfusion in cardiomyocytes (21,51–54). Activation of 
ERK1/2 is involved in the activation of contractile responses through mechanisms involving 
direct phosphorylation of the Ca2+/calmodulin-dependent myosin light chain kinase (MLCK) 
(33,55–57).  
In a seminal review by Spinazzi et al, a case is made for mediation of Ca2+ by orexin 
receptors (58). However, this effect of OX1R and OX2R on Ca2+-release is through IP3 
receptor activation, which, although evident in the hypothalamus, does not impact on the 
contraction of rat ventricular cardiac muscle under basal conditions, where the ryanodine 
receptors (RyR) dominate excitation-contraction (E-C) coupling (59). As such, this may have 
more of a role in pathophysiology of heart failure and arrhythmias (60). Interestingly, the 
dominant expression of IP3-receptors is on the nuclear membrane where they are thought to 
be involved in cardiac hypertrophy (61). 
Conversely, inhibition of ERK attenuates force development by lowering MLC 
phosphorylation in cardiac tissue (62). Because of its central role in the regulation of 
contraction and relaxation of the heart, cTnI is also phosphorylated by OR-B to ensure 
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appropriate function. Changes in the phosphorylation status of cTnI are well documented 
during acute cardiac events and in patients with heart failure (63).  
We have expanded on these observations using human heart tissue samples from heart 
failure patients. So far, a number of studies indicated that there is a dysregulation of the 
orexin system in the CNS in models of heart failure (64–66). Here we further report that in 
adults with heart failure (NYHA classes I to IV) there was a significant negative correlation 
between the severity of clinical symptoms (NYHA class) and OX2R expression. The fact that 
OX2R expression was significantly lower in patients with NYHA classes III/IV compared to 
less symptomatic patients with NYHA class I/II, indicates that OX2R signalling is 
compromised in more severe heart failure. These observations are further supported by the 
findings of Perez et al., where in a heart failure model, HCRTR2/OX2R-deficient mice 
exhibited poorer cardiac function, and greater myocardial scarring (67). Moreover, in the 
same study, differential OX2R expression data from microarray experiments was recorded in 
patients with dilated cardiomyopathy and ischemic cardiomyopathy (67). 
Based on the established role that orexins have in maintaining the awake state, orexin 
antagonism has also been identified as a novel therapeutic approach for the treatment of 
insomnia (68). As such, suvorexant, a non-selective dual orexin (OX1R/OX2R) receptor 
antagonist (DORA), has been approved by the FDA, in 2014, for treating insomnia patients 
with difficulties in sleep onset and/or sleep maintenance (www.acc.org/latest-in-
cardiology/articles/2015/06/16/08/40/new-insomnia-drugs-in-the-context-of-cardiovascular-
disease - BELSOMRA® (suvorexant) package insert: 
www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf). To date, suvorexant 
use has not been associated with any reported adverse cardiovascular safety outcomes; 
however, it must be highlighted that it is unknown whether suvorexant has adverse effects in 
CVD patients, since patients with significant and/or recent CVD (e.g. with acute coronary 
syndrome or congestive heart failure) were excluded from the relevant trials 
(http://www.acc.org/latest-in-cardiology/articles/2015/06/16/08/40/new-insomnia-drugs-in-
the-context-of-cardiovascular-disease). Therefore, and based on the findings from our study 
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and from others (67), the use of orexin antagonists may warrant further assessment and 
careful monitoring for CVD adverse effects, particularly in heart failure patients (69). 
Finally, our human ex vivo study results were also consistent with the in vitro rat data, since 
orexin treatment of human myocardial tissue demonstrated that OR-B, but not OR-A, was 
able to induce ERK1/2 phosphorylation. However, there was no change in Akt 
phosphorylation upon treatment with OR-A or OR-B. The latter could be due to the fact that 
chronic heart failure reduces Akt phosphorylation, so signalling is already compromised at 
basal levels. Indeed, compared to subjects with normal cardiac function, human skeletal 
muscle of heart failure patients demonstrates reduced Akt phosphorylation (70). It should be 
noted that the cardiovascular and musculoskeletal system are interrelated, whereby a 
functional deterioration in one is reflected similarly in the other (71). Differences in the 
phosphorylation of Akt can also be due to species differences, since certain proteins, like 
ERG, are differentially expressed in the rat and human heart (72).  
We also acknowledge certain limitations with our experimental system using healthy young 
adult rats compared to patients used in this study that have certain comorbidities. To date, it 
has proven difficult to find the “perfect” translational in vivo model for CVD. This is primarily 
due to the high level of complexity, as well as heterogeneity of these diseases, in addition to 
potential impact/influence from environmental or genetic factors. Future studies can make 
use of different animal models for examples such as; heart failure, aged rats, or rats fed with 
a high fat diet to generate further data on the involvement of OR-B/OX2R at the cardiac level. 
However, to the best of our knowledge, there is no perfect in vivo model to represent the 
entire repertoire of defects/comorbidities at the cardiac level. 
In summary, our present findings document that OR-B exhibits a protective role on cardiac 
function pre- and post- ischaemia, leading to reduction of the infarct size. We also provide 
novel conclusive evidence that the rat heart expresses functional OXRs and is a source of 
orexins. Cardiac OXRs can also influence contractile tone via mechanisms involving 
phosphorylation of TnI and MLC. Thus, in addition to the known CNS effects of 
orexins/OX2R (5,73), our data illustrate the importance of the OX2R as a potential 
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therapeutic target directly at the heart level, suggesting that targeted use of OX2R specific 
agonists may have a role in the prevention and treatment of CVD. 
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Figure Legends 
Figure 1: Expression of orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the rat and 
human heart. 
Panel A: Quantitative RT-PCR analysis of OX1R and OX2R in the rat hypothalamus (hypo) 
and rat heart (***P<0.001 for heart vs. hypothalamus). 
Panel B: Immunohistochemical analysis of rat heart ventricular sections (n=3) for OX1R (I) 
and OX2R (II). Magnification x400. Negative control (III) confirmed the specificity of the 
immunostaining.  
Panel C: Immunohistochemical analysis of OX1R (I) and OXR2 (II) in rat cardiomyocytes 
and negative control (III). Identical results obtained from four independent experiments; 
measuring at least 50 cells.  
Panel D: Expression of OX1R and OX2R in rat heart compartments (n=3). Lane 1 cDNA 
from left ventricle (LV); Lane 2 cDNA from left auricle; Lane 3 cDNA from septum; Lane 4 
cDNA from right ventricle (RV); Lane 5 cDNA from right auricle; and Lane 6 is DNA marker.  
Panel E: Single-Cell RT-PCR in cardiomyocytes (n=6): Lane-1: -Actin; Lane-2: OX1R; 
Lane-3: negative control; Lane-4: OX2R.  
Panel F: Expression of OX1R and OX2R in different human cardiac compartments: Lane-1: 
aorta; Lane-2: apex of the heart; Lane-3: left atrium (LA); Lane-4: right atrium (RA); Lane-5: 
right auricle; Lane-6: left auricle; Lane-7: left ventricle (LV); Lane-8: right ventricle (RV); 
Lane-9: interventricular septum; and Lane-10: atrioventricular (AV) node.   
Panel G: Expression of prepro-orexin in rat heart chambers (n=3). Prepro-orexin is 
expressed as a 302bp PCR product in the left ventricle (LV) (lane 1), left atrium (LA) (lane 
2), interventricular septum (lane 3), right ventricle (RV) (lane 4), and right atrium (RA) (lane 
5). M=Marker; DNA ladder. 
Panels H and I: Prepro-orexin (PPO) and the cleaved peptides Orexin-A (OR-A) and 
Orexin-B (OR-B) were detected using western blotting, with molecular weights of 15 kDa for 
prepro-orexin, 3.5 kDa and 2.9 kDa for OR-A (H) and OR-B (I), respectively; Lane 1: rat 
heart lysates; and Lane 2: rat hypothalamus lysates (n=3).  
Panel J: Immunohistochemical analysis for OR-A on rat thymus section (I) and rat spleen 
(II). 
Panel K: Immunohistochemical analysis of rat heart ventricular sections (n=3) for OR-A (I) 
and OR-B (II) and negative control (III). Magnification x400.  
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Panel L: Rat cardiomyocyte immunofluorescent analysis of OR-A (I), OR-B (II), and negative 
control (III). Identical results obtained from four independent experiments, measuring at least 
50 cells.  
 
Figure 2: Effects of orexin B (OR-B) on contractility of rat cardiomyocytes and on the 
phosphorylation of troponin I (TnI) and myosin light chain (MLC). 
Using video-edge detection system, changes in cell length of individual cardiomyocytes 
(n=6) were recorded upon challenge with orexins.  
Panel A & B: Superfusion of the myocyte with OR-B (10 nM) increased the strength of 
twitch contraction (**P<0.01).  
Panel A & C: No effect on the amplitude of the Ca
2+
 transient was observed.   
Panel D: Similar effects on the strength of twitch contraction was observed following 
treatment with a specific orexin-2 receptor (OX2R) agonist (OX2Ra: [Ala11, D-Leu15]-Orexin 
B) (*P<0.05).  
Panel E: Addition of an OX1R specific antagonist (OX1R Ant.: SB-408124) did not alter the 
OR-B cardiomyocyte contractile response (*P<0.05).  
Panel F: OR-B was able to induce phosphorylation of troponin I in a concentration 
dependent manner (**P<0.01, ***P<0.001).  
Panel G: OR-B was able to induce phosphorylation of MLC in a concentration dependent 
manner (**P<0.01, ***P<0.001). For the above experiments, equal protein loading was 
confirmed, using β-actin as an internal control. B= basal (no Orexin B). 
 
 
Figure 3: Cardiac functional parameters and infarct size determination following 
ischaemia (n=8). 
Panels3A-C. Panels depict the effects on left rate pressure product (RPP) = heart rate (HR) 
x left ventricular developed pressure (LVDP), following 30 min of ischaemia (45 min to 75 
min) for:  
Panel 3A: Control (Con); pre-treatment: orexin A (OR-A), orexin B (OR-B) or orexin-2 
receptor (OX2R) agonist (OX2Ra) in the in situ rat model (ex vivo; isolated Langendorff 
model) (*P<0.05, compared to control). 
Panel 3B: Control, post-treatment OR-B or OX2Ra in the in situ rat model (*P<0.05, 
compared to control). 
Panel C: Control, bolus pre-treatment OR-A, OR-B, OX2Ra in the in vivo rat model 
(*P<0.05, compared to control). 
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Panels 3D-F. Depict the effects on the left ventricle (LV) infarct size (% LV; transverse 
sections of the rat heart were obtained at the end of the experimental protocol and the 
sections were stained using triphenyl-tetrazolium chloride so that the infarcted tissue 
appears pale, whilst viable tissue stains red). More specifically:  
Panel D: Control; pre-treatment with OR-A, OR-B and OX2Ra in the ex-vivo model 
(***P<0.001, compared to control). 
Panel E: Control; post-treatment with OR-B or OX2Ra in the ex-vivo model (***P<0.001, 
compared to control). 
Panel F: In vivo model with bolus pre-treatment with OR-A, OR-B and OX2Ra prior to 
regional ischaemia and reperfusion (***P<0.001, compared to control). 
 
Figure 4: Orexin B (OR-B)/orexin-2 receptor (OX2R) effects on key signalling pathways 
involved in myocardial protection using the isolated Langendorff perfused rat heart 
model (n=8).  
Panel A: Cardiac functional performance measured and represented as left rate pressure 
product (RPP) in rat hearts pre-treated with control (saline treated), OR-B plus OX1R 
antagonist, OX1R antagonist alone, OR-B plus wortmannin (wort; a PI3Kinase inhibitor), and 
wortmannin alone (*P<0.05 compared to control). 
Panel B: Left ventricle infarct size determination (%LV) in pre-treated hearts with OR-B plus 
OX1R antagonist, OX1R antagonist alone, OR-B plus wortmannin, and wortmannin alone 
(***P<0.001 compared to control). Dotted line across denotes control levels.  
Panel C: OR-B time-dependent treatment and Akt phosphorylation: exposure of rat 
cardiomyocytes to OR-B (100 nM) induced maximal phosphorylation at 5 min. Change in the 
phosphorylation was evident as early as 2 min post-treatment (*P<0.05, ***P<0.001 
compared to basal). 
Panel D: OR-B induced a dose-dependent induction in the phosphorylation status of Akt, 
becoming significant at 1 nM and reaching a plateau at 100 nM (**P<0.01, ***P<0.001 
compared to basal).  
Panel E: OR-B treatment increased the phosphorylation of ERK1/2 compared to basal levels 
(***P<0.001). Isoproterenol (ISO) and Angiotensin-II (Angio-II) were employed as positive 
controls. 
Panel F: inhibition of the MAPK pathway using a selective MAPK inhibitor (U0126) 
abrogates the protective effect of OR-B on LV infarct size (*P<0.05, **P<0.01, ***P<0.001 
compared to control; a: P<0.05 compared to OR-B). 
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Figure 5: Orexin-induced signalling and orexin receptor expression in heart samples 
from cardiac surgery patients. 
Panel A-B: In human heart tissue obtained from patients undergoing coronary artery bypass 
(n=8), both orexin A (OR-A) and orexin B (OR-B) showed no change in Akt phosphorylation 
compared to the non-treated heart tissue (100 nM). Change in the phosphorylation state was 
evident for ERK1/2 signaling in the OR-B treatment group (*P<0.05 compared to control).   
Panel C: Expression of orexin-2 receptor (OX2R) in heart samples from heart failure 
patients (n=54) demonstrated a significant decrease of OX2R in NYHA-II compared to 
NYHA-I patients (ǂP<0.05) and in NYHA-III/IV compared to NYHA-II (*P<0.05) and to NYHA-
I patients († P<0.05). NYHA: New York Heart Association Functional Classification for heart 
failure stages.  
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Supplementary Figure 1: Experimental protocol for the isolated Langendorff perfused 
rat heart and the in vivo model of ischaemia reperfusion (n=8).  
Protocol (1): presents the control pre-treatment study, which consisted of 30 minutes (min) 
stabilisation followed by 30 min global ischaemia and 120 min reperfusion. For the treatment 
groups, hearts were perfused with Tyrode’s+treatment agent for 10 min prior to 30 min 
global ischaemia followed by 120 min reperfusion.  
Protocol (2): presents the post-treatment study group, hearts were perfused with 
Tyrode’s+treatment for 30 min into the start of reperfusion after which the hearts were 
perfused with Tyrode’s only.  
Protocol (3): presents the in vivo rat model of regional ischaemia and reperfusion; the pre-
treatment was with a bolus intravenous (i.v.) injection (e.g. of orexin B 10 nmol) 10 min prior 
to 30 min regional ischaemia and 120 min reperfusion. 
 
Supplementary Figure 2: A: Rat testes (positive control), B and C: Different sections of rat 
heart stained positive for OR-A, D: Rat Heart; a region that is not positive for OR-A; 
demonstrating antibody specificity. Magnification x40 
 
Table 1. Selected key patient characteristics prior to cardiac surgery and tissue collection for 
the heart failure study patients, including age, gender, hypertension, hyperlipidaemia, type 2 
diabetes mellitus, smoking status and body mass index (BMI). Data are presented as 
mean±SEM, or as frequencies.  
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Participants (n) 54 
  
Age (years) 65.2 +/- 1.3 
  
Male gender (%) 50 (92.6) 
  
Hypertension (%) 30 (55.6) 
  
Hyperlipidaemia (%) 31 (57.4) 
  
Type 2 diabetes mellitus (%) 16 (29.6) 
  
Smoking - active (%) 26 (48.1) 
                - ex (%) 13 (24.1) 
  
BMI (Kg/m2)  27.29 +/- 0.50 
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